No cheerleading. RG still looks good, but only the investigator-sponsored trials in Europe are happening. Trying to sell the company, or the patents on RG, or just to line up aome financing.
It's hard to overstate the benefit that the early trials suggest for RG. CIN has been a major concern for years. But more than one approach looked almost as good in its first trials and then fell through (the situation is so desperate that most of them are still used anyway). Makes the patents a tough sell.